- Home
- APLS vs BBIO Comparison
APLS vs BBIO Comparison
Compare APLS & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLS
- BBIO
- Stock Information
- Founded
- APLS 2009
- BBIO 2015
- Country
- APLS United States
- BBIO United States
- Employees
- APLS N/A
- BBIO N/A
- Industry
- APLS Biotechnology: Pharmaceutical Preparations
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- APLS Health Care
- BBIO Health Care
- Exchange
- APLS Nasdaq
- BBIO Nasdaq
- Market Cap
- APLS 4.4B
- BBIO 5.1B
- IPO Year
- APLS 2017
- BBIO 2019
- Fundamental
- Price
- APLS $33.21
- BBIO $26.49
- Analyst Decision
- APLS Buy
- BBIO Strong Buy
- Analyst Count
- APLS 19
- BBIO 13
- Target Price
- APLS $49.89
- BBIO $47.92
- AVG Volume (30 Days)
- APLS 3.2M
- BBIO 2.7M
- Earning Date
- APLS 11-05-2024
- BBIO 11-12-2024
- Dividend Yield
- APLS N/A
- BBIO N/A
- EPS Growth
- APLS N/A
- BBIO N/A
- EPS
- APLS N/A
- BBIO N/A
- Revenue
- APLS $715,216,000.00
- BBIO $217,765,000.00
- Revenue This Year
- APLS $95.59
- BBIO $2,306.97
- Revenue Next Year
- APLS $12.92
- BBIO N/A
- P/E Ratio
- APLS N/A
- BBIO N/A
- Revenue Growth
- APLS 162.10
- BBIO 2209.77
- 52 Week Low
- APLS $24.34
- BBIO $21.62
- 52 Week High
- APLS $73.80
- BBIO $44.32
- Technical
- Relative Strength Index (RSI)
- APLS 53.75
- BBIO 49.05
- Support Level
- APLS $32.88
- BBIO $25.34
- Resistance Level
- APLS $35.71
- BBIO $28.15
- Average True Range (ATR)
- APLS 1.60
- BBIO 1.33
- MACD
- APLS -0.22
- BBIO -0.24
- Stochastic Oscillator
- APLS 36.62
- BBIO 24.73
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.